New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee…
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare neurological condition. Acadia Pharmaceuticals’ investigational treatment for hyperphagia in Prader-Willi…
Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to develop internal talent marketplaces and systems that support upskilling and reskilling their workforce. BioSpace spoke to leaders at Pfizer and…
Embracing Communities of Innovation: Massachusetts Our strategy to transform patients’ lives has always centered on building state-of-the-art research centers within communities that spark innovation. Massachusetts stands as a global hub for life sciences, home to some of the brightest minds…
Layoff Tracker: Rome Trims Already-Small Team Amid Strategic Review 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson cutting hundreds or even thousands of employees. BioSpace will continue to be…
Employee-led initiative supports global partnerships to build stronger, climate-resilient health systems Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to building…
Silent global health crisis threatens lives, driving heart disease, stroke, and kidney failure worldwide The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people lived with hypertension in 2024, yet just over one in…
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index…
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced that the first patient has…
Pharma Giant Expands Into Emerging Psychedelic Therapies With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across…
Critics Warn Plan May Hinder Innovation and Patient Access The FDA’s proposed Rare Disease Evidence Principles review process is a starting point for getting rare disease therapies across the finish line, but industry leaders say there are more concrete steps…
The fight against misinformation goes to the heart of trust in public health We are at a critical juncture. While best estimates conclude that vaccines have saved more than 150 million lives in the past 50 years, the potential for…